James L Januzzi1,2, Milton Packer3, Brian Claggett4, Jiankang Liu4, Amil M Shah4, Michael R Zile5, Burkert Pieske6, Adriaan Voors7, Parul U Gandhi8, Margaret F Prescott9, Victor Shi9, Martin P Lefkowitz9, John J V McMurray10, Scott D Solomon3. 1. Division of Cardiology, Massachusetts General Hospital, Boston (J.L.J.). 2. Cardiometabolic Trials, Baim Institute for Clinical Research, Boston, MA (J.L.J.). 3. Division of Cardiology, Baylor University Medical Center, Dallas, TX (M.P., S.D.S.). 4. Division of Cardiology, Brigham and Women's Hospital, Boston, MA (B.C., J.L., A.M.S.). 5. Division of Cardiology, Medical University of South Carolina, Charleston (M.R.Z.). 6. Division of Cardiology, Charite Hospital, Berlin, Germany (B.P.). 7. Division of Cardiology, University Medical Center Groningen, The Netherlands (A.V.). 8. Division of Cardiology, Yale University Medical Center, New Haven, CT (P.U.G.). 9. Novartis Pharmaceutical Corporation, Hanover, NJ (M.F.P., V.S., M.P.L.). 10. Division of Cardiology, University of Glasgow, United Kingdom (J.J.V.M.).
Abstract
BACKGROUND: Increased activity of IGFBP7 (insulin-like growth factor-binding protein-7) is associated with cellular senescence, tissue aging, and obesity. IGFBP7 may be related to heart failure with preserved ejection fraction, a disease of elderly obese people. METHODS AND RESULTS: In a subset of patients with heart failure with preserved ejection fraction (N=228) randomized to receivesacubitril/valsartan versus valsartan, IGFBP7 concentrations were measured at baseline, 12 weeks, and 36 weeks. Patient characteristics and echocardiographic measures including left atrial (LA) size and volume, ratio of early mitral inflow velocity/annular diastolic velocity, and ratio of early diastole/peak late diastolic velocity were assessed as a function of IGFBP7 concentration. Effect of sacubitril/valsartan on IGFBP7 concentrations was analyzed. With increasing baseline IGFBP7 quartiles, LA size and LA volume index (LAVi) were higher (both P<0.001); modest association between IGFBP7 and higher early mitral inflow velocity/annular diastolic velocity ( P=0.03) and early diastole/peak late diastolic velocity ratio ( P=0.04) was also seen. IGFBP7 concentrations were higher in those with LAVi ≥34 mL/m2 compared with lower LAVi at all time points (all P<0.01). IGFBP7 independently predicted LAVi at baseline even in the presence of NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentrations; highest LAVi was seen in those with elevation in both biomarkers. Treatment with sacubitril/valsartan resulted in lower IGFBP7 concentrations over 36 weeks compared with valsartan (adjusted treatment effect, -7%; P<0.001). CONCLUSIONS: Among patients with heart failure with preserved ejection fraction, concentrations of the cellular senescence biomarker IGFBP7 were associated with abnormalities in diastolic filling and LA dilation. Treatment with sacubitril/valsartan resulted in lower IGFBP7 concentrations compared with valsartan. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00887588.
RCT Entities:
BACKGROUND: Increased activity of IGFBP7 (insulin-like growth factor-binding protein-7) is associated with cellular senescence, tissue aging, and obesity. IGFBP7 may be related to heart failure with preserved ejection fraction, a disease of elderly obesepeople. METHODS AND RESULTS: In a subset of patients with heart failure with preserved ejection fraction (N=228) randomized to receive sacubitril/valsartan versus valsartan, IGFBP7 concentrations were measured at baseline, 12 weeks, and 36 weeks. Patient characteristics and echocardiographic measures including left atrial (LA) size and volume, ratio of early mitral inflow velocity/annular diastolic velocity, and ratio of early diastole/peak late diastolic velocity were assessed as a function of IGFBP7 concentration. Effect of sacubitril/valsartan on IGFBP7 concentrations was analyzed. With increasing baseline IGFBP7 quartiles, LA size and LA volume index (LAVi) were higher (both P<0.001); modest association between IGFBP7 and higher early mitral inflow velocity/annular diastolic velocity ( P=0.03) and early diastole/peak late diastolic velocity ratio ( P=0.04) was also seen. IGFBP7 concentrations were higher in those with LAVi ≥34 mL/m2 compared with lower LAVi at all time points (all P<0.01). IGFBP7 independently predicted LAVi at baseline even in the presence of NT-proBNP (N-terminal pro-B-type natriuretic peptide) concentrations; highest LAVi was seen in those with elevation in both biomarkers. Treatment with sacubitril/valsartan resulted in lower IGFBP7 concentrations over 36 weeks compared with valsartan (adjusted treatment effect, -7%; P<0.001). CONCLUSIONS: Among patients with heart failure with preserved ejection fraction, concentrations of the cellular senescence biomarker IGFBP7 were associated with abnormalities in diastolic filling and LA dilation. Treatment with sacubitril/valsartan resulted in lower IGFBP7 concentrations compared with valsartan. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT00887588.
Authors: Yasmina Bauer; Simon de Bernard; Peter Hickey; Karri Ballard; Jeremy Cruz; Peter Cornelisse; Harbajan Chadha-Boreham; Oliver Distler; Daniel Rosenberg; Martin Doelberg; Sebastien Roux; Oliver Nayler; Allan Lawrie Journal: Eur Respir J Date: 2021-06-24 Impact factor: 16.671
Authors: Arzu Kalayci; W Frank Peacock; John T Nagurney; Judd E Hollander; Phillip D Levy; Adam J Singer; Nathan I Shapiro; Richard K Cheng; Chad M Cannon; Andra L Blomkalns; Elizabeth L Walters; Robert H Christenson; Annabel Chen-Tournoux; Richard M Nowak; Mark D Lurie; Peter S Pang; Peter Kastner; Serge Masson; C Michael Gibson; Hanna K Gaggin; James L Januzzi Journal: ESC Heart Fail Date: 2020-05-14
Authors: Paola Sebastiani; Anthony Federico; Melody Morris; Anastasia Gurinovich; Toshiko Tanaka; Kevin B Chandler; Stacy L Andersen; Gerald Denis; Catherine E Costello; Luigi Ferrucci; Lori Jennings; David J Glass; Stefano Monti; Thomas T Perls Journal: Aging Cell Date: 2021-01-29 Impact factor: 11.005
Authors: Anna Lisowska; Anna Szyszkowska; Małgorzata Knapp; Magda Łapińska; Marcin Kondraciuk; Inga Kamińska; Tomasz Hryszko; Katarzyna Ptaszyńska-Kopczyńska; Karol Kamiński Journal: Biomolecules Date: 2022-02-08
Authors: Alfredo De Giorgi; Alberto Maria Marra; Massimo Iacoviello; Vincenzo Triggiani; Giuseppe Rengo; Francesco Cacciatore; Ciro Maiello; Giuseppe Limongelli; Daniele Masarone; Francesco Perticone; Pasquale Perrone Filardi; Stefania Paolillo; Antonio Mancini; Maurizio Volterrani; Olga Vriz; Roberto Castello; Andrea Passantino; Michela Campo; Pietro Amedeo Modesti; Andrea Salzano; Roberta D'Assante; Michele Arcopinto; Valeria Raparelli; Fabio Fabbian; Angela Sciacqua; Annamaria Colao; Toru Suzuki; Eduardo Bossone; Antonio Cittadini Journal: Intern Emerg Med Date: 2022-04-21 Impact factor: 5.472
Authors: Bernadet T Santema; Vicente Artola Arita; Iziah E Sama; Mariëlle Kloosterman; Maarten P van den Berg; Hans L A Nienhuis; Isabelle C Van Gelder; Peter van der Meer; Faiez Zannad; Marco Metra; Jozine M Ter Maaten; John G Cleland; Leong L Ng; Stefan D Anker; Chim C Lang; Nilesh J Samani; Kenneth Dickstein; Gerasimos Filippatos; Dirk J van Veldhuisen; Carolyn S P Lam; Michiel Rienstra; Adriaan A Voors Journal: Cardiovasc Res Date: 2022-08-24 Impact factor: 13.081